Insulet Presents Results of Omnipod 5 Automated Insulin Delivery System Demonstrated Improved Glycemic Outcomes in Children with Type 1 Diabetes at ADA 2022
- The company reported the extension data from the pivotal trial to evaluate Omnipod 5 automated insulin delivery system in children aged 2 through 5.9yrs. with type 1 diabetes for 12mos.
- The results showed an improvement in time in range (67.6% after 12 mos. of Omnipod 5 use vs 57.2% during standard therapy) and 68.1% during 3mos. pivotal trial; avg. HbA1c (9% vs 7.4% & 6.9%) & was shown to be safe and effective in the 3mos. of trial, percent time in hypoglycemia (<70 mg/dL) was reduced over standard therapy with the median (1.9% vs 2.2% & 1.9%)
- Additionally, no episodes of DKA or severe hypoglycemia were reported. Omnipod 5 is the first tubeless, wearable AID system in the US
Ref: Businesswire | Image: Insulet
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.